Get the Stockscreener App
4.16
6.94%
0.27
After Hours:
4.08
-0.08
-1.92%
Alvotech stock is traded at $4.16, with a volume of 733.06K.
It is up +6.94% in the last 24 hours and down -16.63% over the past month.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
See More
Previous Close:
$3.89
Open:
$3.94
24h Volume:
733.06K
Relative Volume:
1.38
Market Cap:
$1.30B
Revenue:
$548.10M
Net Income/Loss:
$69.50M
P/E Ratio:
18.06
EPS:
0.2303
Net Cash Flow:
$-137.90M
1W Performance:
+0.00%
1M Performance:
-16.63%
6M Performance:
-50.06%
1Y Performance:
-63.15%
1-Day Range:
$3.90
$4.1725
1-Week Range:
$3.65
$4.1725
52-Week Range:
$3.65
$11.85
Alvotech Stock (ALVO) Company Profile
Compare ALVO vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
4.16 | 1.21B | 548.10M | 69.50M | -137.90M | 0.2303 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.76 | 57.56B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
122.23 | 53.17B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.33 | 46.62B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.75 | 38.33B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
485.06 | 21.48B | 3.13B | 1.27B | 1.12B | 26.39 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Nov-04-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-14-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-14-25 | Initiated | UBS | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
Alvotech Stock Plummets to New 52-Week Low of $3.65 - Markets Mojo
ALVO Earnings History & Surprises | EPS & Revenue Results | ALVOTECH SA (NASDAQ:ALVO) - ChartMill
Alvotech to Release Fourth Quarter and Full Year 2025 Financial Results - geneonline.com
Alvotech to Announce Q4 and Full Year 2025 Financial Results on March 18, 2026 - Quiver Quantitative
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Alvotech schedules March 18 earnings, March 19 investor call - Stock Titan
Alvotech (ALVO) Stock Analysis: Exploring A Potential 375% Upside In The Biosimilar Market - DirectorsTalk Interviews
Alvotech : Managers' transactionsALVOTECH - marketscreener.com
Alvotech’s Biosimilar Bet: Why Wall Street Is Suddenly Watching - AD HOC NEWS
Alvotech (ALVOW) Competitors - Meyka
Alvotech (NASDAQ:ALVO) Sets New 12-Month LowShould You Sell? - MarketBeat
Alvotech stock hits 52-week low at 3.89 USD - Investing.com
Alvotech stock hits 52-week low at 3.89 USD By Investing.com - Investing.com UK
Alvotech (NASDAQ:ALVO) Given Average Recommendation of "Reduce" by Analysts - MarketBeat
Alvotech Discloses Intra-Group Transfer of 2.7 Million Shares Within Aztiq Group - TipRanks
Alvotech (NASDAQ: ALVO) discloses 2.7M-share intra-group transfer at $4.74 - Stock Titan
Transactions of Managers and Closely Associated Persons - GlobeNewswire
Alvotech (ALVO) Is Down 9.1% After FDA Rejects AVT05 Over Facility Issues and Legal Probe - simplywall.st
ALVO INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alvotech - GlobeNewswire
Alvotech begins European rollout of first-ever Simponi biosimilar Gobivaz - MSN
Alvotech (NASDAQ:ALVO) Cut to Strong Sell at Zacks Research - Defense World
Alvotech (NASDAQ:ALVO) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
Alvotech stock hits 52-week low at $4.31 amid challenging year - Investing.com Australia
Alvotech (NASDAQ:ALVO) Reaches New 1-Year LowHere's Why - MarketBeat
Alvotech (NASDAQ:ALVO) Trading Down 5.7%Here's Why - MarketBeat
Alvotech (ALVO): A 378% Upside Potential In The Biosimilar Market - DirectorsTalk Interviews
Is There Now an Opportunity in Alvotech (ALVO) After a 64% One-Year Share Price Slide? - simplywall.st
Is Alvotech (ALVO) Pricing Make Sense After A 64% One Year Share Price Slump - Yahoo Finance
Alvotech AVT80 Progress And Sandoz Deals Shape Biosimilar Outlook - Yahoo Finance
How Alvotech Equity Warrant stock performs during Fed tightening cyclesEarnings Overview Summary & Free Safe Capital Growth Stock Tips - mfd.ru
Can Alvotech Equity Warrant maintain its current growth rateQuarterly Trade Summary & Accurate Entry and Exit Point Alerts - mfd.ru
Alvotech (ALVO) Announces Strong Results for Clinical Trial for AVT80 - Finviz
Can Alvotech be recession proofJuly 2025 EndofMonth & Weekly Watchlist for Consistent Profits - mfd.ru
12 Best Penny Stocks That Will Skyrocket - Insider Monkey
Is Alvotech the Next Big Biotech Rocket or Just Hype? Real Talk on This Viral Underdog Stock - AD HOC NEWS
How Alvotech (ALVO) Affects Rotational Strategy Timing - Stock Traders Daily
Alvotech’s AVT03 Biosimilar Gains European Approval - MSN
Alvotech resolves global patent disputes with Regeneron and Bayer over Eylea biosimilar - MSN
Assessing Alvotech (ALVO) Valuation After AVT80 Trial Success And New Sandoz Agreements - simplywall.st
Alvotech Increases Share Capital by $125,000 Through Issuance of 12.5 Million Ordinary Shares - Quiver Quantitative
Alvotech Announces Increase in Number of Own Shares - ChartMill
Alvotech (ALVO) Investor Outlook: Exploring a 331% Potential Upside in the Biosimilars Market - DirectorsTalk Interviews
ALVO Investor News: If You Have Suffered Losses in Alvotech - GlobeNewswire
ALVO INVESTOR ALERT: Hagens Berman Investigates Alvotech - GlobeNewswire
Press releases provided by CNW - Techaeris
Aug Drivers: What is the Moat Score of Alvotech Equity WarrantQuarterly Trade Review & Weekly Setup with ROI Potential - baoquankhu1.vn
Alvotech Faces Securities Claims Investigation - Intellectia AI
Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action InvestigationALVO - morningstar.com
Alvotech Enters Supply and Commercialization Agreements for Canada and Australia & New Zealand Covering Multiple Biosimilar Candidates - 富途牛牛
Are Expanded Sandoz Biosimilar Deals Quietly Reframing Alvotech’s Partnership Strategy and Scale Ambitions (ALVO)? - simplywall.st
Alvotech higher on positive data backing biosimilar to Takeda’s Entyvio - MSN
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):